Ethex Corporation has expanded its recall of morphine tablets on June 16, 2008. The recalled tablets potentially contain twice the dose of morphine that is on the prescription drug label.

Ethex Corporation originally recalled a single lot of morphine tablets on June 9, 2008. The recall has been expanded to include both 60 mg and 30 mg lots of extended release morphine tablets.

The recall expansion is being described as a precaution by Ethex Corporation. There have not been any reports of adverse reactions linked to the tablets.

Serious adverse reactions can develop due to an overdose of an opioid medication, like morphine. Symptoms of an opioid overdose include respiratory distress, low-blood pressure and hypotension.

The Food and Drug Administration (FDA) has listed the following recalled lots: 30mg Tablet/NDC # 58177-320-04: Lots 75090, 77846, 77847, 80048, 83320, 89661, 89665, 90252 through 90258, and 93284 and 60mg Tablet/NDC # 58177-330-04: Lots 91762 (previously reported), 75091, 75092, 77848 through 77851, 82517, 82518, 83333, 83817, 83862, 84111, 84112, 84315, 84900, 85326, 85335, 85807, 86270 through 86276, 87723, 87939, 88007, 89083, 89668, 89669, 89821, 90260 through 90272, and 91763 through 91765.

Defective drug attorneys are working to prevent the serious illnesses and injuries that can result from faulty prescription drugs.

ETHEX Corporation is recalling one lot of 60 mg morphine sulfate tablets due to a risk of overdose. The tablets were manufactured with double the dose of morphine sulfate that is on the label, which could cause serious adverse reactions.

The lot affected by the recall is number 91762. No additional lots are being recalled.

The morphine tablets were released between April 15 and April 27, 2008. They are under the ETHEX label.

As with all opioid medication, the consequences of an overdose can be fatal. An overdose of morphine may result in difficulty breathing and lowered blood pressure.

To this date, the U.S. Food and Drug Administration (FDA) has not received any reports of adverse side effects.

Defective drug attorneys are working to help prevent serious consequences of faulty prescription medication by holding drug manufactures responsible for their negligence.

On March 25^{th, California regulators delayed the electronic tracking of prescription drugs for two years. The California State Board of Pharmacy voted 12-0 to allow prescription drug manufacturers, distributors and pharmacies an additional two years to begin electronically tracking prescription drugs from the manufacturer to the patient.The requirement was already delayed by the California State Legislation in 2007. Now, the pharmaceutical industry has until January 1, 2011. The delay is intended to allow the pharmaceutical industry time to set up computer systems that would comply with the first ever requirement to track prescriptions.}

The requirement was instituted in California after a recall of fake Lipitor.

There are defective drug attorneys currently working on cases that involve the serious and fatal illnesses that result from defective drugs.